Homocysteinemia After XXXX Pregnancy Disorders at Term.

@entity1 @entity101 @entity1255 @entity65 @entity413
BACKGROUND: Results from a number of long-term follow-up studies have suggested that @entity101 in pregnancy are associated with increased risk of @entity65 later in life. More recently, this putative relationship has been substantiated with findings of elevated cardiovascular risk factors, such as lipid profiles and @entity413 , in @entity1 with a history of @entity101 . @entity1255 is a sensitive indicator of increased risk but data on @entity1255 levels in @entity1 with a history of @entity101 are inconsistent. DESIGN: This cohort study included 279 @entity1 with a history of @entity101 at term and 85 @entity1 with a history of uncomplicated pregnancies who participated in the Hypitat Risk Assessment Study (HyRAS). METHODS: Blood samples for total @entity1255 determination were taken 2.5 years postpartum. @entity1255 levels were determined in plasma using an immunoassay. RESULTS: @entity1 with a history of @entity101 had significant higher median @entity1255 levels (10.66    mol/L) 2.5 years postpartum compared with @entity1 with a history uncomplicated pregnancies (9.82    mol/L; p=0.002). @entity1 with a history of @entity101 had a higher risk of having a @entity1255 level in the highest quartile (odds ratio 3.4, 95% confidence interval 1.5-7.6). CONCLUSION: At 2.5 years postpartum, @entity1 with a history @entity101 had higher @entity1255 levels than @entity1 who had uncomplicated pregnancies. Although higher @entity1255 levels might be a potential link between a history of @entity101 and @entity65 risk later in life, the clinical implications remain an area for future research.
